This is a preview of subscription content, log in via an institution to check access.
Literatur
Burger M, Zaak D, Stief CG et al. (2007) Photodynamic diagnostics and noninvasive bladder cancer: Is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol (in press)
Burger M, Burger SJ, Denzinger S et al. (2006) Elevated microsatellite instability at selected tetranucleotide repeats does not correlate with clinicopathologic features of bladder cancer. Eur Urol 50: 770–775
Denzinger S, Mohren K, Knuechel R et al. (2006) Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses. Hum Pathol 37: 143–151
Denzinger S, Burger M, Knuechel R et al. (2007) Clinically relevant reduction in the risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of a prospective randomized study. Urology (in press)
Goebell PJ, Vom Dorp F, Rodel C et al. (2006) Noninvasive and invasive bladder cancer: diagnostics and treatment. Urologe A 45: 873–884
Goebell PJ, Otto T, Suhr J, Rubben H (2002) Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. J Urol 168: 72–75
Hungerhuber E, Stepp H, Kriegmair M et al. (2007) Seven years‘ experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 69: 260–264
Obermann EC, Meyer S, Hellge D et al. (2004) Fluorescence in situ hybridization detects frequent chromosome 9 deletions and aneuploidy in histologically normal urothelium of bladder cancer patients. Oncol Rep 11: 745–751
Oosterlinck W, Lobel B, Jakse G et al. (2002) European Association of Urology (EAU) Working Group on Oncological Urology. Guidelines on bladder cancer. Eur Urol 41: 105–112
Stief C, Zaak D, Stockle M et al. (2006) Diagnostik und Therapie des Harnblasenkarzinoms. Standards und Perspektiven. Urologe A 45(Suppl 4): 90–96
Stoehr R, Zietz S, Burger M et al. (2005) Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer. Eur Urol 47: 58–63
Tritschler S, Scharf S, Karl A et al. (2007) Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis. Eur Urol 51: 403–407
Oers JM van, Wild PJ, Burger M et al. (2007) FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol 12 (in press)
Oers JM van, Adam C, Denzinger S et al. (2006) Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer 119: 1212–1215
Wild PJ, Giedl J, Stoehr R et al. (2007) Genomic aberrations are rare in urothelial neoplasms of patients 19 years or younger. J Pathol 211: 18–25
Wild PJ, Kunz-Schughart LA, Stoehr R et al. (2005) High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int J Oncol 27: 385–391
Wild PJ, Krieg RC, Seidl J et al. (2005) RNA expression profiling of normal and tumor cells following photodynamic therapy with 5-aminolevulinic acid-induced protoporphyrin IX in vitro. Mol Cancer Ther 4: 516–528
Wild PJ, Herr A, Wissmann C et al. (2006) Gene expression profiling of progressive papillary non-invasive carcinomas of the urinary bladder. Clin Cancer Res 11: 4415–4429
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Denzinger, S., Hartmann, A., Hofstaedter, F. et al. Interdisziplinäres Networking für klinische und molekulare Fragestellungen beim nicht-muskelinvasiven Urothelkarzinom der Harnblase. Urologe 46, 1126–1128 (2007). https://doi.org/10.1007/s00120-007-1458-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-007-1458-7